CG Oncology is a privately held oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with bladder cancer. At CG Oncology we see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life.

Our lead candidate, CG0070, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. CG0070 is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with CG0070 in combination with OPDIVO® (nivolumab).

Whitesun Healthcare Ventures

WI Harper Group

Song Hong Fang

Ally Bridge Group

ORI Capital

Perseverance Capital Management

Camford Capital

Kissei Pharmaceutical

Decheng Capital

RA Capital Management

Sirona Capital

Acorn Bioventures

Longitude Capital

Malin Corporation

Foresite Capital

BVF Partners

TCG Crossover

Avidity Partners

Janus Henderson Investors

CG Oncology

Join Dr. Vijay Kasturi, CG Oncology’s Chief Medical Officer, at the 2024 American Urological Association (AUA) Annual Meeting in #SanAntonioTX. Dr. Kasturi will share how CG Oncology is advancing the fight against bladder cancer with innovative solutions at our booth #100 from May 3-5 at 12:30 pm CDT. He will provide insights into our pipeline, clinical trials, and the potential of cretostimogene grenadenorepvec as a therapeutic option.

📅 May 3-5, Booth #100
⏰ 12:30 pm (10 to 15 mins) 

Our team is looking forward to sharing our latest advancements for #NMIBC patients.

👉 More on the event here: auanet.org/AUA2024

#CGOncology #BladderCancer #UroOncology #CancerResearch #ClinicalTrial #Therapeutics #DrugDevelopment #Immunotherapy #TherapeuticAdvances #AUA24

Each year, more than 80,000 people in the United States receive a #bladdercancer diagnosis. 🩺

CG Oncology is committed to addressing the unmet needs of these patients and focused on developing bladder-saving therapeutics. Join us in the Bladder Cancer Advocacy Network (BCAN) 2024 Walks to End Bladder Cancer, happening all across the country. These walks are a celebration of hope as we unite to advance research and provide support for patients and their loved ones. 

👉 Find a walk near you at https://bit.ly/3x65qD3 

#CGOncology #EndBladderCancer #BladderCancerAwareness #BladderCancer #UroOncology #CancerResearch #MedicalResearch #CancerSupport #BCANWalk2024 

CG Oncology is excited to share our updated results on cretostimogene grenadenorepvec at the 2024 American Urological Association (AUA) Annual Meeting in San Antonio, TX from May 3-6, 2024.  

Dr. Robert Svatek of UT Health San Antonio and Dr. Mark Tyson, M.D., M.P.H of Mayo Clinic Scottsdale, AZ, will present abstracts highlighting cretostimogene, while an oral presentation will feature the interim 12-month Phase 3 data from the BOND-003 trial. If you are attending #AUA2024, we invite you to join us and meet our team at booth #100. Cretostimogene has the potential to be a backbone therapy for patients diagnosed with bladder cancer. 

📖 For more information, read the full release: https://bit.ly/3PEUbI0 

#CGOncology #BladderCancer #CancerResearch #UroOncology #MedicalResearch #CancerResearch #ClinicalTrial #Therapeutics #DrugDevelopment #Immunotherapy #OncologyBreakthrough #TherapeuticAdvances #AUA24

🧬 Excitement is building for #AUA2024! Join us at the 2024 American Urological Association (AUA) Annual Meeting, taking place in #SanAntonioTX from May 3-6.

Meet CG Oncology’s Medical Team at Booth #100 and explore the MoA of cretostimogene grenadenorepvec through Virtual Reality. This is an incredible opportunity to gain insights into the future of #bladdercancer therapy and learn how our pipeline and clinical trial programs can complement your practice. More details coming soon!

🗓️ Learn more here: auanet.org/AUA2024

#CGOncology #BladderCancer #CancerResearch #UroOncology #MedicalResearch #CancerResearch #ClinicalTrial #Therapeutics #DrugDevelopment #Immunotherapy #OncologyBreakthrough #TherapeuticAdvances #AUA24

CG Oncology is growing! We recently welcomed some exceptionally talented team members who will be joining with us in Attacking Bladder Cancer for a Better Tomorrow™. Welcome to CG Oncology Adrian Knoth, M.Sc, PMP, Anthony Fernandez, PharmD, MSL-BC, Davis Bauman, Shelja Patel, PharmD, RPh, BCMAS and Victoria D'Anthony. If you are interested in joining our team of intelligent and passionate team members that share our Vision, Mission and Values, please visit our Careers Page: https://lnkd.in/e-UiUYdg

Today marks another step forward in our ongoing effort to transform the treatment landscape for #bladdercancer. The first patient has been dosed in the PIVOT-006 Phase 3 trial, which is investigating cretostimogene grenadenorepvec as an investigational drug for the treatment of Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (#NMIBC) following transurethral resection of the bladder tumor (#TURBT).  

With over 80,000 individuals diagnosed annually with bladder cancer in the United States, the PIVOT-006 study addresses the unmet medical need for patients facing limited treatment options. Dr. Neal Shore, MD, FACS of Carolina Urologic Research Center confirmed the potential impact of this therapy: “Cretostimogene is a novel therapy which has the potential to be a paradigm shift in how we might manage the ongoing burden of this highly recurrent aspect of bladder cancer.”
 
Learn more about the PIVOT-006 study and how CG Oncology is committed to developing novel bladder-sparing therapeutics that improve patient outcomes.

📄 Read the full release: https://bit.ly/49AOqTO 
 
#Urology #ClinicalTrials #UrothelialCancer #CancerResearch #MedicalResearch #PatientCare #Immunotherapy #Therapeutics #CGOncology #PIVOT006

Merck is a leading pharmaceutical company with a strong focus on oncology treatments. It has a diverse portfolio of cancer therapies and a significant presence in the market.

Merck

Gilead Sciences is a renowned biopharmaceutical company known for its innovative treatments in various therapeutic areas, including oncology.

Gilead Sciences

ImmunityBio is a biotechnology company specializing in developing immunotherapies for cancer and other diseases. It has been actively involved in advancing novel cancer treatment approaches.

ImmunityBio

Bristol Myers Squibb is a global biopharmaceutical company with a strong emphasis on oncology research and development. It has a diverse portfolio of cancer treatments.

Bristol Myers Squibb

Ferring Pharmaceuticals is a multinational pharmaceutical company with a focus on developing innovative therapies, including gene therapies for cancer treatment.

Ferring Pharmaceuticals

CG Oncology is a biotechnology company focused on developing therapeutic antibodies for the treatment of cancer. The company has unveiled encouraging results for its lead product, CG0070, which is an investigational oncology virus being evaluated for the treatment of solid tumors.

Audit Committee Chair & Independent Board Director

Audit Committee Chair & Board Member

Senior Advisor & Entrepreneur In Residence

Board Chair & Audit Committee Chair

Chief Executive Officer & Board Member

Chief Business Officer & Principal Financial Officer

Vice President, Corporate Development & Strategy

Global Head, Commercial Assessment and Due Diligence

Global Head (Executive Director), Strategic Evaluation

Director, Global Business Development, Mergers and Acquisitions

Director, Marketing

Director, Business Development

Manager, Business Development

Market Analyst, New Product Planning

Medical Center Representative

Validation Engineer, Manufacturing

Chief Executive Officer | Corporate Strategist | Company Builder | Deal Maker

Susan Graf

Associate

Director, Business Operations

VP, Business Development

Manager, Business Operations

Clinical Research Associate

Academic Researcher

Calvin Lai

Director, Clinical Operations (APAC)

Manager Project Management and Bussiness Development

Manager Medical Writing

Medical Writer

Director, Clinical Operations (APAC) at CG Oncology

Bruce Choi

Chief Financial Officer

US CFO

CFO, Biopharma NA

Chief Financial Officer, Vaccines Business Unit

Global Finance Lead, Enbrel, Biopharma Business Unit

CFO, North America

Corporate Controller

Worldwide Director Finance

Sr. Manager, Finance, Research and Development

Sr. Analyst, External Reporting

Senior Associate

Chief Financial Officer at CG Oncology

Corleen Roche

Head, Clinical Data Management

Head, Partner Relations at Platform Life Sciences

Vice President, Data Management

Director, Data Management Technologies, Innovation and Enablement

Manager, Clinical Programming Operations

Instructor, School of Nursing Health Sciences

Manager, Clinical Programming

Michael L.

President & Chief Operating Officer

Board Member

Chairman

Member - Investor

Chief Executive Officer

President

Vice President, UroInjectables

Vice President, Orthopedics Business Unit

Director, Sales

Area Vice President

Associate Director, Global eBusiness

District Sales Manager/Regional Account Manager

Hospital Sales Consultant

CNS Specialist

Pharmaceutical Sales Specialist

CEO, President, and COO of Biotech Company | Driving Growth and Innovation | DE&I Champion and Patient Advocate

Ambaw Bellete

Director, Information Technology

Senior Director, IT Strategy, Operations, & Governance

Information Technology Management Consultant

State Farm Agent Owner

Account Executive (Client Valeant Pharmaceuticals)

Acting Account Executive/Service Delivery Manager (Client: Allergan)

Senior Manager, Information Systems/Technology

Principal/Senior Consultant

Validation Consultant/Validation Project Manager

Project Manager

Operations Specialist

Information Technology Executive | Transformation Professional | Business Technologist

Trung Thai

Associate Director, CMC

Associate Director, QC

Manager, QC/AD

Associate Scientist

Development Associate II

Sr. Biological Scientist (QC and Analytical Development)

OPS Technician (QC and Analytical Development)

Intern (Analytical Development)

Research Technician

Research Assistant

Baron McFadden

Director of Organizational & Talent Development

Principal

Professional Leadership Development  & Career Coach

Director Human Resources

Manager Talent Acquisition

Technical HR Consultant

Senior Recruiting Consultant

Senior HR Recruiting Consultant

Senior Technical Recruiting Consultant

Technical Recruiting Consultant

Director of Organizational & Talent Development @ CG Oncology | Master's in Organizational Leadership

Diane Hopkins

Director of R&D

Associate Director of R&D

Group Leader in Stem Cell Research Department

Postdoctoral Research Fellow

Director of R&D at CG Oncology, Inc.

Shihpei

Chief Technical Officer

Senior Vice President, CMC Development and GMP Manufacturing

Vice Presiden, Biologics Drug Substance Development

Executive Director, Bioprocess Development and Analytical Science

Senior Director, BioProcess and Conjugation Process Development

Principal Scientist

Sr. Engineer

Strategic and Technical Leadership/ Organizational Transformation/ Governance/ Biologics Drug Development

Swapnil B.

Senior Director

Associate Director - Senior Consultant Upstream Development

Senior Consultant Upstream Development

Project Manager - Upstream Process Development

Senior Scientist USP

Scientist

Post-Doc

Senior Director at CG Oncology

Anke Kayser

Chief Medical Officer

Vice President, Clinical Development/Medical Affairs

Senior Vice President Scientific Affairs

Vice President Medical Affairs

Head of US Medical Affairs - Oncology

Senior Medical Director & Global Medical Affairs Lead - Avelumab  & Genitourinary Cancer Portfolio

Medical Director, Oncology Medical Affairs

Physician

Chief Medical Officer, CG Oncology

Vijay Kasturi

Director, Quality Assurance - Commercial GMP

Senior Director, Quality Assurance

Director, Quality Assurance

GMP Quality Assurance Professional - Biologics and Pharmaceuticals - Drug Development/Commercial Drugs

news impact assignment basic	general	May 7, 2024 9:24 PM	e48f8823
public peers	general	May 7, 2024 9:24 PM	f60eb486
news daily refresh	general	Aug 23, 2024 12:20 AM	3a282963
news processing daily refresh	general	Aug 23, 2024 6:52 AM	f9a8cf63
news impact assignment daily	general	Aug 23, 2024 7:10 AM	8b0d5556
news processing basic	general	May 7, 2024 9:24 PM	7ee0a2fc
company summary	general	Aug 23, 2024 9:38 AM	190211b4
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	64022e62
crunchbase profile	general
li profile	general	May 7, 2024 9:24 PM	c74f956b
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 7, 2024 9:24 PM	b2d7e83a
bundesanzeiger	filings
financials download nd	financials
private financials	financials

CGON

COM:CGONCOLOGY

CG Oncology

Last Close

32.34

22/11 21:00

Market Cap

2.19B

Beta: -

Volume Today

397.20K

Avg: -